Indian medtech sector could reach $30B in the next decade, AdvaMed says | Sanofi, Lead Pharma join to develop drugs for autoimmune diseases | Study: Drug-resistant malaria on the verge of spreading into India

February 24, 2015
DIA Global SmartBrief
News on diagnostic and therapeutic innovations and regulatory science

Top StorySponsored By
Indian medtech sector could reach $30B in the next decade, AdvaMed says
The medtech industry in India could be worth $25 billion to $30 billion over the next 10 years with the proper regulatory structure and appropriate government policies, AdvaMed India Working Group Chairman Sanjay Banerjee said Thursday. The group is also calling for a lower duty on lifesaving devices and is urging India's government to establish an ecosystem for the sector's growth. The Economic Times (India)/Press Trust of India (2/19)
Share: LinkedInTwitterFacebookGoogle+Email
The New You Starts Here.
There's never been a more urgent need for healthcare leaders with "big picture" vision, and more than 80% of new jobs in healthcare now require a graduate degree. Earn your online Healthcare MBA from FIU Online in just 18 months and take your first step toward increased marketability. Start here.
Sanofi, Lead Pharma join to develop drugs for autoimmune diseases
Sanofi and Lead Pharma agreed to collaborate in the discovery, development and marketing of the latter's lead drug candidates intended to treat a wide variety of autoimmune conditions, including inflammatory bowel disease and rheumatoid arthritis. The collaboration will focus on drugs that target the ROR gamma(t) nuclear hormone receptors. The partners did not reveal the value of the deal, but Lead said it will get an upfront fee, milestone payments and sales royalties from Sanofi. PharmaTimes (U.K.) (2/18), Genetic Engineering & Biotechnology News (2/18)
Share: LinkedInTwitterFacebookGoogle+Email
5 tips for managing negative online comments
The Internet gives your customers a voice online, but what can you do when that voice is yelling negative comments? With 5 tips, you can learn how to positively respond and help direct the conversation. Read the article and learn the 5 ways to respond positively.

Asia PacificSponsored By
Study: Drug-resistant malaria on the verge of spreading into India
A study in The Lancet Infectious Diseases has found that drug-resistant malaria is threatening to spread from Southeast Asia to India and into Africa. Blood samples from 940 people with malaria from 55 sites in Myanmar, as well as border areas of Bangladesh and Thailand, showed that 39% carried the K13 or kelch gene mutation, and a map showed that the estimated regional prevalence of resistance was as close as 15 miles from the India border. "We need a more vigorous international effort to address this issue in border regions," said Philippe Guerin, director of the Worldwide Antimalarial Resistance Network. Yahoo/Agence France-Presse (2/20)
Share: LinkedInTwitterFacebookGoogle+Email
Building Workplace Trust 2015
Interaction Associates' 6th annual research study tracking trust on the job, Building Workplace Trust, is out, and more than half of employees surveyed give their organizations low marks for trust and leadership. Yet this year's findings again point to how high trust leads to better outcomes and financial results — and even boosts innovation.

North AmericaSponsored By
Valeant buys Salix on strength of IBS drug's expected FDA approval
Canada-based Valeant Pharmaceuticals has purchased North Carolina-based Salix Pharmaceuticals for $10.1 billion. Valeant hopes that Salix's irritable bowel syndrome drug Xifaxan will gain FDA approval by May. Valeant made an unsuccessful attempt last year to buy Allergan, which makes Botox. ABC News/The Associated Press (2/22), Bloomberg (2/22)
Share: LinkedInTwitterFacebookGoogle+Email
New antibiotic development is slow in U.S., study finds
A study in Clinical Infectious Diseases found only two antibiotic medications were approved between 2008 and 2012, compared with 16 between 1983 and 1987, raising concerns about the ability to treat drug-resistant infections. Bacterial infections with no effective treatments cause 23,000 deaths each year in the U.S. Bloomberg (2/19)
Share: LinkedInTwitterFacebookGoogle+Email
MedImmune partners with NIST to research drug-development tools
AstraZeneca's MedImmune unit signed a five-year deal with the National Institute of Standards and Technology to research tools that can be used to develop new drugs or improve the efficacy of existing treatments. The deal will center on biopharmaceuticals. Research funding for the initial year of the collaboration will be provided by MedImmune. American City Business Journals/Washington, D.C./BizBeat Blog (2/20)
Share: LinkedInTwitterFacebookGoogle+Email
Takeda signs GI-drug-development pact with U.K. university
Takeda Pharmaceutical and Queen Mary University of London agreed to collaborate in the research and development of new drugs for gastrointestinal disorders. Gastrointestinal sensory and motor mechanisms related to motility and functional bowel disorders will be the focus of the collaboration. Under the agreement, Takeda's GI drug discovery unit will work on several areas of research with neurogastroenterology and immunology experts from Queen Mary. Pharmaceutical Business Review Online (2/20)
Share: LinkedInTwitterFacebookGoogle+Email
Report: Minimally invasive surgical tools market to reach $14.13B by 2019
A MarketsandMarkets report predicts the market for minimally invasive surgical instruments will grow to $14.13 billion by 2019. The report cited the lower cost of care from minimally invasive surgeries, the superiority of these procedures over conventional open surgeries and the growing number of surgeries among the elderly as major factors expected to drive growth. (2/20)
Share: LinkedInTwitterFacebookGoogle+Email
Featured Press Releases
DIA News
9th DIA Conference in Japan for Asian New Drug Development
Hear key thought leaders from Asia and around the world share their valuable experiences and insights as we convene the 9th DIA Conference in Japan for Asian New Drug Development on April 20-21 to ensure that medical needs are met in the era of globalized drug development. Special "hot topics" will include ICH E17 guidelines and new initiatives by Asian regulatory authorities to catalyze the creation of fresh ideas.
Share: LinkedInTwitterFacebookGoogle+Email
Global Forum reports on risk-based monitoring
Stretching less into more has become a familiar clinical trial refrain. Your new Global Forum reports on risk-based monitoring, an emerging approach that delivers the most benefit to your trials through monitoring targeted to the areas of greatest risk and also focuses on conversations about delivering the right treatment to the right patient at the right time that will continue at our upcoming 27th Annual EuroMeeting and 8th Annual Clinical Forum in Paris. Enjoy the streamlined navigation and new functionality of this Special Open Access Issue. NO login required: Forward to share the DIA member experience with a friend!
Share: LinkedInTwitterFacebookGoogle+Email
Your only obligation in any lifetime is to be true to yourself."
-- Richard Bach,
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about DIA ->About DIA | Meetings & Trainings | News & Publications | Membership
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Lisa Gough
Advertising:  Meryl Harold
  P: 202.407.7828

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information